{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:59:02Z","timestamp":1780617542060,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011779","name":"Brien Holden Vision Institute Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.apjo.2025.100138","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T21:54:38Z","timestamp":1736978078000},"page":"100138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Role of caffeine in slowing progression of myopia: 1-year results from a prospective, longitudinal clinical trial"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-7114","authenticated-orcid":false,"given":"Huy D.M.","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-6128","authenticated-orcid":false,"given":"Thao T.X.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3355-7951","authenticated-orcid":false,"given":"Tuan D.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-3641","authenticated-orcid":false,"given":"Monica","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minas","family":"Coroneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-6193","authenticated-orcid":false,"given":"Padmaja","family":"Sankaridurg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2025.100138_bib1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100138_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100138_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/APO.0000000000000414","article-title":"A meta-analysis assessing change in pupillary diameter, accommodative amplitude, and efficacy of atropine for myopia control","volume":"10","author":"Tran","year":"2021","journal-title":"Asia Pac J Ophthalmol (Philos)"},{"key":"10.1016\/j.apjo.2025.100138_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100138_bib5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","article-title":"Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study","volume":"41","author":"Joachimsen","year":"2021","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib6","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/OPX.0000000000000037","article-title":"Maximum atropine dose without clinical signs or symptoms","volume":"90","author":"Cooper","year":"2013","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.apjo.2025.100138_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/jop.2023.0173","article-title":"Impact of various concentrations of low-dose atropine on pupillary diameter and accommodative amplitude in children with myopia","volume":"40","author":"Tran","year":"2024","journal-title":"J Ocul Pharm Ther"},{"key":"10.1016\/j.apjo.2025.100138_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12177-008-9013-3","article-title":"Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: a 36-month pilot study","volume":"1","author":"Trier","year":"2008","journal-title":"J Ocul Biol Dis Info"},{"key":"10.1016\/j.apjo.2025.100138_bib9","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/bjo-2021-320920","article-title":"Oral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish children","volume":"107","author":"Trier","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib10","first-page":"523","article-title":"Distribution of adenosine receptors in human sclera fibroblasts","volume":"14","author":"Cui","year":"2008","journal-title":"Mol Vis"},{"key":"10.1016\/j.apjo.2025.100138_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1755-3768.2009.01559.x","article-title":"Adenosine receptor protein changes in guinea pigs with form deprivation myopia","volume":"88","author":"Cui","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib12","unstructured":"Arumugam B., et al. Topically applied caffeine, a non-selective adenosine receptor antagonist, alters emmetropizing responses in infant monkeys. In , Aston University, Birmingham, UK: 2017.International Myopia Conference."},{"key":"10.1016\/j.apjo.2025.100138_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108438","article-title":"Topically instilled caffeine selectively alters emmetropizing responses in infant rhesus monkeys","volume":"203","author":"Smith","year":"2021","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.apjo.2025.100138_bib14","first-page":"1623","article-title":"Effect of caffeine on the intraocular pressure in patients with primary open angle glaucoma","volume":"5","author":"Chandra","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9578308","article-title":"Effect of single administration of coffee on pupil size and ocular wavefront aberration measurements in healthy subjects","volume":"2016","author":"Bardak","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.apjo.2025.100138_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/OPTH.S96394","article-title":"Effect of coffee (caffeine) against human cataract blindness","volume":"10","author":"Varma","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/OPX.0b013e3182357f79","article-title":"Myopia progression rates in urban children wearing single-vision spectacles","volume":"89","author":"Donovan","year":"2012","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.apjo.2025.100138_bib18","unstructured":"Bartlett J. November 2019.Introduction to sample size calculation using G*\u2009Power."},{"key":"10.1016\/j.apjo.2025.100138_bib19","first-page":"133","article-title":"Effects of 7-methylxanthine on form-deprivation myopia in pigmented rabbits","volume":"5","author":"Nie","year":"2012","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1167\/iovs.17-22337","article-title":"The adenosine receptor antagonist, 7-methylxanthine, alters emmetropizing responses in infant macaques","volume":"59","author":"Hung","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100138_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1755-3768.2009.01688.x","article-title":"Effects of 7-methylxanthine on the sclera in form deprivation myopia in guinea pigs","volume":"89","author":"Cui","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100138_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01708-2","article-title":"Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial","volume":"11","author":"Cui","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjo.2025.100138_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100138_bib25","first-page":"1535","article-title":"Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression","volume":"104","author":"Fu","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1385\/JMN:26:2-3:239","article-title":"Adenosine-dopamine interactions revealed in knockout mice","volume":"26","author":"Salmi","year":"2005","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.apjo.2025.100138_bib27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/bjo.83.12.1370","article-title":"Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine","volume":"83","author":"Trier","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100138_bib28","first-page":"523","article-title":"Distribution of adenosine receptors in human sclera fibroblasts","volume":"14","author":"Cui","year":"2008","journal-title":"Mol Vis"},{"key":"10.1016\/j.apjo.2025.100138_bib29","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1167\/iovs.09-3998","article-title":"Genetic deletion of the adenosine A2A receptor confers postnatal development of relative myopia in mice","volume":"51","author":"Zhou","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100138_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000502529","article-title":"Effects of 7-methylxanthine on deprivation myopia and retinal dopamine release in chickens","volume":"63","author":"Liu","year":"2020","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.apjo.2025.100138_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/iovs.65.11.10","article-title":"Acute effects of oral caffeine intake on human global-flash mfERG responses: a placebo-controlled, double-masked, balanced crossover study","volume":"65","author":"Vera","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100138_bib32","series-title":"Handbook of Aqueous Solubility Data","author":"Yalkowsky","year":"2010"},{"key":"10.1016\/j.apjo.2025.100138_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.exer.2018.05.020","article-title":"Adenosine receptor distribution in rhesus monkey ocular tissue","volume":"174","author":"Beach","year":"2018","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.apjo.2025.100138_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.exer.2013.04.015","article-title":"Caffeine eye drops protect against UV-B cataract","volume":"113","author":"Kronschl\u00e4ger","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.apjo.2025.100138_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/jcr.2011.0016","article-title":"UV-induced apoptosis in lens: prevention by caffeine","volume":"1","author":"Varma","year":"2011","journal-title":"J Caffeine Res"},{"key":"10.1016\/j.apjo.2025.100138_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.exer.2016.01.017","article-title":"Unconventional aqueous humor outflow: a review","volume":"158","author":"Johnson","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.apjo.2025.100138_bib37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/OPX.0000000000002187","article-title":"Baseline factors associated with myopia progression and axial elongation over 30 months in children 5 to 12 years of age","volume":"101","author":"Weise","year":"2024","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.apjo.2025.100138_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/iovs.64.6.4","article-title":"IMI - the dynamic choroid: new insights, challenges, and potential significance for human myopia","volume":"64","author":"Ostrin","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098925000052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098925000052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T11:30:58Z","timestamp":1740310258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098925000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2162098925000052"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100138","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of caffeine in slowing progression of myopia: 1-year results from a prospective, longitudinal clinical trial","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100138"}}